Main Article Content
Endometrial Cancer, miR-421, miR-548ag, Biomarkers, Meta Analysis
Objective: This research is to explore the relationship in immune related biomarkers and prognosis in endometrial cancer (EC).
Method: This article searched relevant databases and literature, and ultimately included 13 articles for meta-analysis. During the literature screening process, irrelevant literature, as well as literature published in comments and academic conferences were excluded. Among the included literature, there are 6 articles related to miR-421 and 7 articles related to miR-548ag. The data processing of Meta-analysis adopts statistical methods.
Result: The combined specificity and SROC curve results of meta-analysis showed that miR-421 and miR-548ag possess high diagnostic value for EC. At the same time, sensitivity analysis was conducted on the overall survival rate of OS, and no significant impact was found on combined HR and 95% CI in any study. This indicates that miR-421 and miR-548a possess an essential influence on the prognosis of EC and demonstrates the reliability of this analysis.
Conclusion: The relevant outcomes suggest that miR-421 and miR-548ag may be biomarkers for the prognosis of endometrial cancer. These findings have important guiding significance for a deeper understanding of the pathogenesis, pathological and physiological changes, and clinical treatment of endometrial cancer. It is essential to conduct more research for validating the role of these biomarkers in the prognosis of endometrial cancer.
Bernard L , Kwon J S , Simpson A N , et al. The Levonorgestrel Intrauterine System for Prevention of Endometrial Cancer in Women With Obesity: A Cost-effectiveness Study[J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2021, 76(10):605-606.
 Jamieson A , Huvila J , Thompson E F , et al. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification[J]. Gynecologic oncology, 2022, 165(2):201-214.
Atakul, Tolga,Altinkaya, S. Ozlem,Abas, Burcin Irem,Yenisey, Cigdem.Serum Copper and Zinc Levels in Patients with Endometrial Cancer[J].Biological trace element research.,2020,195(1):46-54.
Siegenthaler F , Lindemann K , Epstein E , et al. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification[J]. Gynecologic oncology, 2022, 165(2):230-238.
 Inoue F , Sone K , Toyohara Y , et al. Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer[J]. Biochemical and Biophysical Research Communications, 2022, 601:123-128.
 Post C C B , Westermann A M , Boere I A , et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)[J]. Gynecologic oncology, 2022, 165(2):223-229.
Akildzhonov F R , Buziashvili J I , Stilidi I S , et al. Biomarkers in patients after chemotherapy[J]. Medical Alphabet, 2021(19):49-53.
 Hu X , Dai Z , Pan R , et al. Long-term transplantation human menstrual blood mesenchymal stem cell loaded collagen scaffolds repair endometrium histological injury[J]. Reproductive Toxicology, 2022, 109:53-60.
 Mielikhova T V , Gryshchenko O V , Lazurenko V V , et al. Optimization of diagnostic studies in patients with adenomiosis and/or hyperplastic processes of endometrium[J]. Reproductive Endocrinology, 2021(58):34-39.
 Kazantseva E V , Tral T G , Tolibova G K . Clinical and anamnestic data and morphofunctional characteristics of the endometrium in women with uterine developmental anomalies[J]. Journal of Obstetrics and Women S Diseases, 2021, 70(2):5-12.
J Rubio-Pérez,R Hernández,T Hernández,B Doger,V Casado,V Moreno.Dostarlimab for the treatment of endometrium cancer and other solid tumors.[J].Drugs of today.,2021,57(3):187-197.
 Jackson C C , Cantrell L , Erickson B K , et al. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium[J]. Journal of Clinical Oncology, 2021, 39(15_suppl):5527-5527.
 Deshmukh B D , Malpani A , Gosavi A V , et al. HISTOPATHOLOGICAL STUDY OF ENDOMETRIUM IN WOMEN WITH ABNORMAL UTERINE BLEEDING[J]. International Journal of Scientific Research, 2021:30-33.
 Weelden W , Reijnen C , Bronsert P , et al. The cut-off for estrogen and progesterone receptor in endometrial cancer revisited: an ENITEC collaboration study[J]. Human Pathology, 2021, 109:80-91.
 Zmen S , Kurt S , Ilgen O , et al. Comparison of MRI, CA-125 and HE-4 in determining the depth of myometrial invasion in cases with endometrial cancer[J]. Journal of Clinical and Investigative Surgery, 2021, 6(1):22-29.
Cintesun, Feyza Nur Incesu,Kerimoglu, Ozlem Secilmis,Cintesun, Ersin,Nergiz, Suleyman,Acar, Hasan,Celik, Cetin.The relationship between KRAS LCS6 polymorphism and endometrium cancer[J].Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology,2020,40(7):988-993.
Arslan, Ayse Kubra Karaboga,Pasayeva, Leyla,Esen, Merve Ayse,Tugay, Osman.Synergistic Growth Inhibitory Effects of Eryngium kotschyi Extracts with Conventional Cytotoxic Agents: Cisplatin and Doxorubicin against Human Endometrium Cancer Cells[J].Current pharmaceutical biotechnology,2022,23(5):740-748.
 Reid H , MKMD Oca, Fayanju O M , et al. 92741 Racial differences in patient-reported distress among women with endometrial cancer[J]. Journal of Clinical and Translational, Science 2021, 5(s1):86-87.
 Editorial A . Proceedings of the Expert Council "Treatment of inoperable endometrial cancer in Russia: issues that have not yet been addressed"[J]. Tumors of Female Reproductive System, 2021, 17(1):65-69.